Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Housecleaning | Main | Stocking Stuffers, of a Sort »

December 10, 2004

An Economist Who Gets It

Email This Entry

Posted by Derek

Alex Tabarrok has finished up his short series on me-too drugs, and he's done a fine job of hitting the nail on the head. It's gratifying to see people from outside the field who really know what they're talking about:

"(Marcia) Angell is also skeptical that me-too drugs can have different effects in different people.  Frankly, I was shocked at this argument. Every clinical trial that has ever been run demonstrates that the same drugs have different effects in different people - it's hardly a surprise that different drugs have different effects.  And me-toos are different - different enough not to violate the patent on the innovator drug almost certainly means different enough to have different effects in some people.  My local supermarket carries at least a dozen different styles of peanut butter, a fact of which I approve, but Angell thinks two angiotensin-converting-enzyme (ACE) inhibitors may be one too many (p.90).  Give me a break. 

Finally, it's important to recognize that small changes can actually make for important improvements.  What could be more me-too than a once-a-day pill replacing a twice-a-day pill?  Yet, to dismiss this change is to overlook the people factor.  A once-a-day regime that people stick to is much better than a twice-a-day regime that people fail to follow.  Forget the chemical structure the economics says a drug that people actually take is a better drug."

Comments (5) + TrackBacks (0) | Category: "Me Too" Drugs


COMMENTS

1. Joe Decker on December 10, 2004 11:37 AM writes...

The criticisms of so-called "me too" drugs drives me nuts as well, I'm signficantly nauseated to one of the PPIs, but not Nexium, if my memory that they're fairly chemically related is correct (and my memory may very well be faulty here, I am not a chemist), I'm deeply grateful for the extra option.

Permalink to Comment

2. Scott S. on December 10, 2004 1:14 PM writes...

Nice to see someone to whom people pay attention is writing on this subject. When I try to talk to people about drug companies and issues such as 'me-too' drugs, it is difficult to break through. However, there are many persuasive arguments one can make to expand people's attitudes.

Really, though, it is up to the drug companies to improve their image. In my experience, a lot of people seem extremely angry at pharma for some reason, thinking they are taking advantage of people.

Once they understand that it takes many years and over 800 million dollars to get a drug through clinical trials, and there is no guarantee that the drug will pass muster, they may change their minds.

Permalink to Comment

3. zp2k on December 10, 2004 4:30 PM writes...

The analysis here neglects a key issue that underlies the outrage, though, which is one of opportunity cost. It’s easy enough to dismiss the idea that no benefit accrues to society from the development of each additional ACE inhibitor. It’s a slightly more difficult question whether there are other, more neglected, conditions that would be getting more attention if the balance of expected profits were different. It’s also hard to argue that the margins associated with different classes of drugs accurately reflect society’s long-term interests.



Are there really so few targets out there that it makes sense to chase the returns (non-zero, sure, but diminishing) from the umpteenth statin? Will the US really benefit more from another therapy for erectile disfunction than from, say, better antimalarial drugs? I think these sorts of questions underlie many of the more heated criticisms…

Permalink to Comment

4. The Novice Chemist on December 10, 2004 5:44 PM writes...

Not to pick nits, but the United States will almost certainly not benefit directly from a better anti-malarial drug, seeing as how we have no malaria in the United States.

I'm guessing that those areas that are neglected are neglected for a reason, profit or science, probably both.

Permalink to Comment

5. zp2k on December 10, 2004 7:06 PM writes...

Sorry - I guess I was trying to bring two thoughts into the discussion simultaneously. For the more immediate of the two, replace malaria with the orphan indication of your choice.

The other is the question of whether long-term US interests wouldn't be better served by an incentive system more tilted toward global health issues, but that's probably a discussion for another day.

Permalink to Comment


EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Days Off
Shuffling the Departments
Funding Undergraduate Summer Research
J. Appl. Drivel or Gibberish Lett.? Choices, Choices.
Molecular Printing of Drug Molecules. Say What?
Pfizer Walks Again By Night
Gitcher SF5 Groups Right Here
Changing A Broken Science System